Abstract
Denosumab, the human monoclonal antibody to RANKL, was approved for the treatment of osteoporosis with its ease of administration once every 6 months.
We report a case of a 74-year-old male patient, who has developed chronic osteomyelitis of the jaw possibly associated with a single denosumab dose for the treatment of glucocorticoid-induced osteoporosis. Extensive osteolytic changes associated with diffuse sclerosis and sequester formation were found in the left lower molar region on panoramic X-ray and CT. Subsequently, sequestration was also observed in the left upper molar edentulous region.
Based on this case report, we suggest that medical-dental collaboration, sharing of the administered medication record and enlightenment of patients are important for the treatment of anti-resorptive agent-related osteomyelitis/osteonecrosis of the jaw. Additionally, it is suggested that teriparatide might lead to an early healing process.
